The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment [0.03%]
溶瘤单纯疱疹病毒治疗胶质母细胞瘤的现状
Hong-My Nguyen,Dipongkor Saha
Hong-My Nguyen
Glioblastoma (GBM) is a lethal primary malignant brain tumor with no current effective treatments. The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes simplex viru...
Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib [0.03%]
重组黏液瘤病毒和奥拉西替尼对兔肺移植性横纹肌肉瘤的治疗效果研究
Laura V Ashton,Barbara Graham,Maryam F Afzali et al.
Laura V Ashton et al.
Purpose: Rhabdomyosarcomas (RMS) are difficult tumors to treat with conventional therapies. Publications indicate that oncolytic virotherapy (OV) could benefit cancer patients with tumors that are refractory to convention...
Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development [0.03%]
病毒受体相互作用和病毒中和：溶瘤病毒研发的启示
Nadishka Jayawardena,John T Poirier,Laura N Burga et al.
Nadishka Jayawardena et al.
Oncolytic viruses (OVs) are replication competent agents that selectively target cancer cells. After penetrating the tumor cell, viruses replicate and eventually trigger cell lysis, releasing the new viral progeny, which at their turn will ...
Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus [0.03%]
诱导合胞体形成的溶细胞性对 myxoma 病毒的溶瘤潜力的影响
Chase Burton,Mee Y Bartee,Eric Bartee
Chase Burton
Introduction: Cancer has become one of the most critical health issues of modern times. To overcome the ineffectiveness of current treatment options, research is being done to explore new therapeutic modalities. One such ...
Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development [0.03%]
病毒-受体相互作用：肿瘤溶瘤病毒发展的结构见解
Nadishka Jayawardena,Laura N Burga,John T Poirier et al.
Nadishka Jayawardena et al.
Recent advancements in oncolytic virotherapy commend a special attention to developing new strategies for targeting cancer cells with oncolytic viruses (OVs). Modifications of the viral envelope or coat proteins serve as a logical mean of r...
Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma [0.03%]
条件性复制的溶瘤腺病毒治疗胶质母细胞瘤的临床前及临床研究进展
Juri Kiyokawa,Hiroaki Wakimoto
Juri Kiyokawa
Replication conditional oncolytic human adenovirus has long been considered a promising biological therapeutic to target high-grade gliomas (HGG), a group of essentially lethal primary brain cancer. The last decade has witnessed initiation ...
Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes [0.03%]
定向进化在筛选具有所需表型的肿瘤溶瘤RNA病毒中的作用
Sergei S Zainutdinov,Galina V Kochneva,Sergei V Netesov et al.
Sergei S Zainutdinov et al.
Viruses have some characteristics in common with cell-based life. They can evolve and adapt to environmental conditions. Directed evolution can be used by researchers to produce viral strains with desirable phenotypes. Through bioselection,...
Bingtao Tang,Zong Sheng Guo,David L Bartlett et al.
Bingtao Tang et al.
Background: Oncolytic viruses selectively infect cancer cells while avoiding infection of normal cells. Usually, selectivity is demonstrated by injecting a virus into tumor-bearing mice and observing infection and lysis o...
Erratum: Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum] [0.03%]
Erratum：包括Rigvir和常规疗法在恶性黑色素瘤中的溶瘤病毒治疗[ corrections ]
Hani M. Babiker,Irbaz Bin Riaz,Muhammad Husnain et al.
Hani M. Babiker et al.
[This corrects the article on p. 11 in vol. 6, PMID: 28224120.].
Published Erratum
Oncolytic virotherapy. 2019 Jan 4:8:1. DOI:10.2147/OV.S196145 2019
Jonathan G Pol,Matthew J Atherton,Byram W Bridle et al.
Jonathan G Pol et al.
Oncolytic activity of the MG1 strain of the Maraba vesiculovirus has proven efficacy in numerous preclinical cancer models, and relied not only on a direct cytotoxicity but also on the induction of both innate and adaptive antitumor immunit...